Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch. 

This encouraged the study’s authors, who had feared any history of smoking on a regular basis would do permanent, irreversible damage to a patient's cardiovascular health. 

Researchers examined data from nearly 60,000 adults, focusing on individuals who have been diagnosed with Cannabis Use Disorder. 

The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.

How common is it for patients to present with overlapping cardiac, renal and metabolic issues? A new analysis in JAMA Cardiology explored that very question.

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

Access to cannabis is skyrocketing across the United States, but much more research is still needed on its long-term side effects.